By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to ...
Even so the deal solidifies Venture Global’s place in the public markets with an impressive $50 billion market cap. And it ...
HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US ...
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...
Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...
The IPO trend remains robust in 2025, driven by strong retail investor interest and a shift from FPIs to the primary market.
The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...
Cell therapy biotech Aurion is moving forward with plans to IPO despite a pending lawsuit from one of its existing investors.
Venture Global's IPO represents a test for investor appetite for fossil fuel projects in the Trump administration.
The stock market trading debut comes as incoming President Trump has said he plans to boost America’s energy production.